Next Article in Journal
Proteomic Analysis of Niemann-Pick Type C Hepatocytes Reveals Potential Therapeutic Targets for Liver Damage
Next Article in Special Issue
Irradiation Suppresses IFNγ-Mediated PD-L1 and MCL1 Expression in EGFR-Positive Lung Cancer to Augment CD8+ T Cells Cytotoxicity
Previous Article in Journal
Neurotherapeutics for Attention Deficit/Hyperactivity Disorder (ADHD): A Review
Previous Article in Special Issue
Perspectives and Issues in the Assessment of SMARCA4 Deficiency in the Management of Lung Cancer Patients
Review

EGFR Status Assessment for Better Care of Early Stage Non-Small Cell Lung Carcinoma: What Is Changing in the Daily Practice of Pathologists?

by 1,2
1
Laboratory of Clinical and Experimental Pathology, CHU Nice, FHU OncoAge, Pasteur Hospital, Université Côte d’Azur, 06108 Nice, France
2
CHU Nice, FHU OncoAge, Hospital-Integrated Biobank BB-0033-00025, Université Côte d’Azur, 06000 Nice, France
Academic Editor: Lucas Treps
Cells 2021, 10(8), 2157; https://doi.org/10.3390/cells10082157
Received: 6 August 2021 / Revised: 18 August 2021 / Accepted: 19 August 2021 / Published: 21 August 2021
(This article belongs to the Special Issue Molecular and Cellular Mechanisms of Lung Cancers)
The recent emergence of novel neoadjuvant and/or adjuvant therapies for early stage (I-IIIA) non-small cell lung carcinoma (NSCLC), mainly tyrosine kinase inhibitors (TKIs) targeting EGFR mutations and immunotherapy or chemo-immunotherapy, has suddenly required the evaluation of biomarkers predictive of the efficacy of different treatments in these patients. Currently, the choice of one or another of these treatments mainly depends on the results of immunohistochemistry for PD-L1 and of the status of EGFR and ALK. This new development has led to the setup of different analyses for clinical and molecular pathology laboratories, which have had to rapidly integrate a number of new challenges into daily practice and to establish new organization for decision making. This review outlines the impact of the management of biological samples in laboratories and discusses perspectives for pathologists within the framework of EGFR TKIs in early stage NSCLC. View Full-Text
Keywords: non-small cell lung carcinoma; early stage; targeted therapies; EGFR; molecular tests non-small cell lung carcinoma; early stage; targeted therapies; EGFR; molecular tests
Show Figures

Figure 1

MDPI and ACS Style

Hofman, P. EGFR Status Assessment for Better Care of Early Stage Non-Small Cell Lung Carcinoma: What Is Changing in the Daily Practice of Pathologists? Cells 2021, 10, 2157. https://doi.org/10.3390/cells10082157

AMA Style

Hofman P. EGFR Status Assessment for Better Care of Early Stage Non-Small Cell Lung Carcinoma: What Is Changing in the Daily Practice of Pathologists? Cells. 2021; 10(8):2157. https://doi.org/10.3390/cells10082157

Chicago/Turabian Style

Hofman, Paul. 2021. "EGFR Status Assessment for Better Care of Early Stage Non-Small Cell Lung Carcinoma: What Is Changing in the Daily Practice of Pathologists?" Cells 10, no. 8: 2157. https://doi.org/10.3390/cells10082157

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop